

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**FORM S-8  
REGISTRATION STATEMENT  
UNDER  
THE SECURITIES ACT OF 1933**

---

**Mednax, Inc.**

(Exact name of registrant as specified in its charter)

---

**Florida**  
(State or other jurisdiction of  
incorporation or organization)

**26-3667538**  
(IRS Employer  
Identification No.)

**1301 Concord Terrace  
Sunrise, Florida 33323**  
(Address of Principal Executive Offices)

**Mednax, Inc. Amended and Restated 2008 Incentive Compensation Plan**  
(Full title of the plan)

---

**Dominic J. Andreano, Esq.  
Executive Vice President,  
General Counsel and Secretary  
Mednax, Inc.  
1301 Concord Terrace  
Sunrise, Florida 33323**  
(Name and address of agent for service)

**(954) 384-0175**  
(Telephone number, including area code, of agent for service)

---

**Copies to:**

**Joshua M. Samek, Esq.  
DLA Piper LLP (US)  
200 South Biscayne Boulevard  
Suite 2500  
Miami, Florida 33131-5341  
(305) 423-8500**

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

---

**CALCULATION OF REGISTRATION FEE**

---

Title of securities to be registered	Amount to be registered (1)	Proposed maximum offering price per share (2)	Proposed maximum aggregate offering price (2)	Amount of registration fee
Common Stock, \$0.01 par value, to be issued under the Mednax, Inc. Amended and Restated 2008 Incentive Compensation Plan	7,200,000	\$29.48	\$212,256,000	\$23,157.13

- (1) Pursuant to Rule 416 of the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional shares of common stock, \$0.01 par value (the "Common Stock"), of Mednax, Inc. (the "Registrant") which become issuable under the Mednax, Inc. Amended and Restated 2008 Incentive Compensation Plan (the "Plan") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of Common Stock. In addition, if any Awards (as defined in the Plan) are forfeited, expire or otherwise terminate without issuance of the underlying shares of Common Stock, or any Award is settled for cash, or otherwise does not result in the issuance of all or a portion of the shares of Common Stock underlying such Award, the shares of Common Stock underlying those Awards, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance, again be available for delivery with respect to Awards under the Plan; provided, however, that shares of Common Stock tendered or withheld to pay the exercise price for any Award or to pay taxes relating to any Award shall not again be available for delivery with respect to Awards under the Plan and, provided further, that Stock Appreciation Rights that are settled in shares of Common Stock shall count against the shares of Common Stock issuable under the Plan based upon the full number of shares of Common Stock that are subject to the Award.
- (2) Estimated solely for the purpose of calculating the registration fee in accordance with Rules 457(c) and (h) of the Securities Act on the basis of the average of the high and low price of a share of Common Stock as reported by the New York Stock Exchange on August 2, 2021.

---

## EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed by Mednax, Inc., a Florida corporation (the “Registrant”), for the purpose of registering an additional 7,200,000 shares of its common stock, \$0.01 par value per share (“Common Stock”), issuable pursuant to the Mednax, Inc. Amended and Restated 2008 Incentive Compensation Plan (the “Plan”). The Registrant’s shareholders approved the amendment and restatement of the Plan to, among other things, increase the number of shares of Common Stock available for issuance under the Plan at the Registrant’s Annual Meeting of Shareholders on May 12, 2021.

Pursuant to Instruction E of Form S-8, the contents of the previously filed Registration Statements on Form S-8 (File Nos. 333-151272, 333-181667 and 333-231826), as filed with the Securities and Exchange Commission (the “SEC”) on May 30, 2008, May 24, 2012 and May 30, 2019, respectively, as amended, are incorporated herein by reference, except to the extent supplemented, amended, or superseded by the information set forth or incorporated herein.

## Part II. INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

### Item 3. Incorporation of Documents by Reference.

The following documents, which have been filed with the SEC, are hereby incorporated by reference into this registration statement:

- (a) The Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 18, 2021;
- (b) The Registrant's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2021 and June 30, 2021, filed with the SEC on May 7, 2021 and August 6, 2021, respectively;
- (c) The Registrant's Current Reports on Form 8-K filed with the SEC on May 14, 2021 and May 17, 2021, respectively;
- (d) The Registrant's Proxy Statement on Schedule 14A filed with the SEC on March 23, 2021; and
- (e) The description of the Registrant's common stock contained in the Registration Statement on Form 8-A (Registration No. 001-12111) filed with the SEC on September 4, 1996 by Pediatrix Medical Group, Inc., a Florida corporation and the Registrant's predecessor, and any amendments to such Registration Statement filed subsequently thereto, including all amendments or reports filed for the purpose of updating such description.

In addition, all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (not including any information furnished under Items 2.02, 7.01 or 9.01 of Form 8-K, which information is not incorporated by reference herein) prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated herein by reference and to be a part of this registration statement from the date of filing of such documents. Any statement contained in a document incorporated herein by reference will be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein, or in a subsequently filed document incorporated herein by reference, modifies or supersedes the statement. Any statement modified or superseded will not be deemed, except as modified or superseded, to constitute a part of this registration statement.

### Item. 8 Exhibits

<u>Exhibit Number</u>	<u>Description</u>
4.1	<a href="#"><u>Composite Articles of Incorporation of Mednax, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Annual Report on Form 10-K for the period ended December 31, 2013).</u></a>
4.2	<a href="#"><u>Amended and Restated By-laws of Mednax, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K dated November 6, 2018).</u></a>
5.1	<a href="#"><u>Opinion of DLA Piper LLP (US).</u></a>

- 10.1 [Mednax, Inc. Amended and Restated 2008 Incentive Compensation Plan \(incorporated by reference to Exhibit A to the Company's Definitive Proxy Statement on Schedule 14A, filed with the SEC on March 23, 2021\).](#)
- 10.2 [Mednax, Inc. Form of Non-Qualified Stock Option Agreement for Non-Qualified Stock Options Awarded Under the 2008 Incentive Compensation Plan \(incorporated by reference to Exhibit 10.17 to the Company's Annual Report on Form 10-K for the year ended December 31, 2008\).](#)
- 10.3 [Mednax, Inc. Form of Restricted Stock Agreement for Restricted Stock Awarded Under the 2008 Incentive Compensation Plan \(incorporated by reference to Exhibit 10.18 to the Company's Annual Report on Form 10-K for the year ended December 31, 2008\).](#)
- 23.1 [Consent of PricewaterhouseCoopers LLP.](#)
- 23.2 [Consent of DLA Piper LLP \(US\) \(contained in its opinion filed as Exhibit 5.1 hereto\).](#)
- 24.1 [Power of Attorney \(contained on the signature pages of this Registration Statement\).](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Sunrise, State of Florida on this 6th day of August, 2021.

**Mednax, Inc.**

By: /s/ Mark S. Ordan

Mark S. Ordan  
Chief Executive Officer

## POWER OF ATTORNEY

Each person whose signature appears below hereby appoints Mark S. Ordan, Dominic J. Andreano and C. Marc Richards such person's true and lawful attorney-in-fact, each acting alone, with full powers of substitution and resubstitution, with authority to execute in the name of each such person, and to file with the SEC, together with any exhibits thereto and other documents therewith, any and all amendments (including without limitation post-effective amendments) to this registration statement necessary or advisable to enable the registrant to comply with the Securities Act of 1933, as amended, and any rules, regulations and requirements of the SEC in respect thereof, which amendments may make such other changes in the registration statement as the aforesaid attorney-in-fact executing the same deems appropriate. Pursuant to the requirements of the Act, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/s/ Mark S. Ordan</u> Mark S. Ordan	Chief Executive Officer and Director (Principal Executive Officer)	August 6, 2021
<u>/s/ C. Marc Richards</u> C. Marc Richards	Chief Financial Officer (Principal Financial Officer)	August 6, 2021
<u>/s/ John C. Pepia</u> John C. Pepia	Chief Accounting Officer (Principal Accounting Officer)	August 6, 2021
<u>/s/ Guy P. Sansone</u> Guy P. Sansone	Director and Chair of the Board	August 6, 2021
<u>/s/ Karey D. Barker</u> Karey D. Barker	Director	August 6, 2021
<u>/s/ Waldemar A. Carlo, M.D.</u> Waldemar A. Carlo, M.D.	Director	August 6, 2021
<u>/s/ Paul G. Gabos</u> Paul G. Gabos	Director	August 6, 2021
<u>/s/ Manuel Kadre</u> Manuel Kadre	Director	August 6, 2021
<u>/s/ Thomas A. McEachin</u> Thomas A. McEachin	Director	August 6, 2021
<u>/s/ Roger J. Medel, M.D.</u> Roger J. Medel, M.D.	Director	August 6, 2021
<u>/s/ Michael A. Rucker</u> Michael A. Rucker	Director	August 6, 2021
<u>/s/ John M. Starcher, Jr.</u> John M. Starcher, Jr.	Director	August 6, 2021
<u>/s/ Shirley A. Weis</u> Shirley A. Weis	Director	August 6, 2021



**DLA Piper LLP (US)**  
200 South Biscayne Boulevard  
Suite 2500  
Miami, Florida 33131-5341  
www.dlapiper.com  
T 305.423.8500  
F 305.437.8131

August 6, 2021

Mednax, Inc.  
1301 Concord Terrace  
Sunrise, Florida 33323

**Re: Registration Statement on Form S-8 for the Mednax, Inc. Amended and Restated 2008 Incentive Compensation Plan**

Ladies and Gentlemen:

On or about the date hereof, Mednax, Inc., a Florida corporation (the "Company"), is filing with the Securities and Exchange Commission (the "Commission") a Registration Statement on Form S-8 (the "Registration Statement"), under the Securities Act of 1933, as amended (the "Act"). The Registration Statement relates to the offering and sale by the Company of up to an additional 7,200,000 shares of the Company's common stock, par value \$0.01 per share (the "Common Stock"), to be issued under the Mednax, Inc. Amended and Restated 2008 Incentive Compensation Plan (the "Plan"). We have acted as counsel to the Company in connection with the preparation and filing of the Registration Statement.

In connection therewith, we have examined and relied upon the original or a copy, certified to our satisfaction, of (i) the Amended and Restated Articles of Incorporation and Amended and Restated Bylaws of the Company, each as amended to the date hereof; (ii) records of corporate proceedings of the Company related to the Plan; (iii) the Registration Statement and exhibits thereto; and (iv) such other documents and instruments as we have deemed necessary for the expression of the opinions herein contained. In making the foregoing examinations, we have assumed the genuineness of all signatures and the authenticity of all documents submitted to us as originals, and the conformity to original documents of all documents submitted to us as certified or photostatic copies. We have also assumed that the offer and sale of shares of Common Stock complies and will comply in all respects with the terms, conditions and restrictions set forth in the Registration Statement and the Plan. As to various questions of fact material to this opinion, we have relied, to the extent we deemed reasonably appropriate, upon representations of officers or directors of the Company and upon documents, records and instruments furnished to us by the Company, without independently checking or verifying the accuracy of such documents, records and instruments.

Based upon the foregoing examination, we are of the opinion that assuming that (i) the Company maintains an adequate number of authorized and unissued shares of Common Stock available for issuance pursuant to the Plan and (ii) the consideration, if any, required to be paid in connection with the issuance of underlying shares of Common Stock issued pursuant to the Plan is actually received by the Company as provided in the Plan, the shares of Common Stock issued pursuant to the Plan will be duly authorized, validly issued, fully paid and nonassessable.

This opinion is rendered solely in connection with the transactions covered hereby. This opinion may not be relied upon for any other purpose, without our prior written consent.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not admit that we come within the category of persons whose consent is required by Section 7 of the Act or the rules and regulations of the Commission thereunder.



The opinions expressed herein are specifically limited to the laws of the State of Florida and the federal laws of the United States of America and speak only as of the date hereof. We assume no obligation to update or supplement such opinions to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

Sincerely,

/s/ DLA Piper LLP (US)

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Mednax, Inc. of our report dated February 18, 2021 relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting, which appears in Mednax, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2021.

/s/ PricewaterhouseCoopers LLP

Miami, Florida

August 6, 2021